Methods of coating a device using anti-thrombin heparin

Synthetic resins or natural rubbers -- part of the class 520 ser – Synthetic resins – From carbohydrate or derivative as a reactant

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S350000, C530S402000, C623S920000

Reexamination Certificate

active

07045585

ABSTRACT:
Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.

REFERENCES:
patent: 2824092 (1958-02-01), Thompson
patent: 3616935 (1971-11-01), Love et al.
patent: 3676612 (1972-07-01), Merrill et al.
patent: 3842061 (1974-10-01), Andersson et al.
patent: 4055635 (1977-10-01), Green et al.
patent: 4213962 (1980-07-01), Miura et al.
patent: 4301153 (1981-11-01), Rosenberg
patent: 4340589 (1982-07-01), Uemura et al.
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4446126 (1984-05-01), Jordan
patent: 4448718 (1984-05-01), Yannas et al.
patent: 4465623 (1984-08-01), Chanas et al.
patent: 4496550 (1985-01-01), Lindahl et al.
patent: 4510084 (1985-04-01), Eibl et al.
patent: 4526714 (1985-07-01), Feijen et al.
patent: 4585754 (1986-04-01), Meisner et al.
patent: 4613665 (1986-09-01), Larm
patent: 4623718 (1986-11-01), Collen
patent: 4634762 (1987-01-01), Feijen et al.
patent: 4656161 (1987-04-01), Herr
patent: 4678671 (1987-07-01), Feijen et al.
patent: 4689323 (1987-08-01), Mitra et al.
patent: 4731073 (1988-03-01), Robinson
patent: 4745180 (1988-05-01), Moreland et al.
patent: 4863907 (1989-09-01), Sakurai et al.
patent: 4920194 (1990-04-01), Feller et al.
patent: 4935204 (1990-06-01), Seidel et al.
patent: 4987181 (1991-01-01), Bichon et al.
patent: 4990502 (1991-02-01), Lormeau et al.
patent: 5002582 (1991-03-01), Guire et al.
patent: 5023078 (1991-06-01), Halluin
patent: 5061750 (1991-10-01), Feijen et al.
patent: 5071973 (1991-12-01), Keller et al.
patent: 5084273 (1992-01-01), Hirahara
patent: 5134192 (1992-07-01), Feijen et al.
patent: 5159050 (1992-10-01), Onwumere
patent: 5171264 (1992-12-01), Merrill
patent: 5182259 (1993-01-01), Kita
patent: 5182317 (1993-01-01), Winters et al.
patent: 5222971 (1993-06-01), Willard et al.
patent: 5262451 (1993-11-01), Winters et al.
patent: 5270046 (1993-12-01), Sakamoto et al.
patent: 5275838 (1994-01-01), Merrill
patent: 5280016 (1994-01-01), Conrad et al.
patent: 5308617 (1994-05-01), Halluin
patent: 5310881 (1994-05-01), Sakurai et al.
patent: 5319072 (1994-06-01), Uemura et al.
patent: 5330907 (1994-07-01), Philapitsch et al.
patent: 5338770 (1994-08-01), Winters et al.
patent: 5364350 (1994-11-01), Dittmann
patent: 5436291 (1995-07-01), Levy et al.
patent: 5455040 (1995-10-01), Marchant
patent: 5510418 (1996-04-01), Rhee et al.
patent: 5529986 (1996-06-01), Larsson et al.
patent: 5556708 (1996-09-01), Horl et al.
patent: 5589516 (1996-12-01), Uriyu et al.
patent: 5652014 (1997-07-01), Galin et al.
patent: 5741852 (1998-04-01), Marchant et al.
patent: 5741881 (1998-04-01), Patnaik
patent: 5762944 (1998-06-01), Inoue et al.
patent: 5782908 (1998-07-01), Cahalan et al.
patent: 5843172 (1998-12-01), Yan
patent: 5851229 (1998-12-01), Lentz et al.
patent: 5855618 (1999-01-01), Patnaik et al.
patent: 5866113 (1999-02-01), Hendriks et al.
patent: 5876433 (1999-03-01), Lunn
patent: 5879697 (1999-03-01), Ding et al.
patent: 5891196 (1999-04-01), Lee et al.
patent: 5944753 (1999-08-01), Galin et al.
patent: 5945457 (1999-08-01), Plate et al.
patent: 5955438 (1999-09-01), Pitaru et al.
patent: 6024918 (2000-02-01), Hendriks et al.
patent: 2001/0007063 (2001-07-01), Oyama et al.
patent: 2001/0034336 (2001-10-01), Shah et al.
patent: 0 081 853 (1983-06-01), None
patent: 0 098 814 (1984-01-01), None
patent: 0 137 356 (1985-04-01), None
patent: 0 344 068 (1989-11-01), None
patent: 0 345 616 (1989-12-01), None
patent: 2 635 019 (1990-02-01), None
patent: 89/09624 (1989-10-01), None
patent: 90/01332 (1990-02-01), None
patent: WO 95/05400 (1995-02-01), None
Radoff et al., “Radioreceptor Assay for Advanced Glycosylation End Products,” Diabetes, vol. 40, pp. 1731-1738, Dec. 1991.
Rolf Axen et al., “Chemical Fixation of Enzymes to Cyanogen Halide Activated Polysaccharide Carriers,” Eur J. Biochem., vol. 18, pp. 351-360 (1971).
Joachim Kohn et al., “A New Approach (Cyano-Transfer) for Cyanogen Bromide Activation of Sepharose at Neutral pH, which Yields Activated Resins, Free of Interfering Nitrogen Derivatives,” Biochemical and Biophysical Research Communications, vol. 107, No. 3, pp. 878-884 (1982).
Chemical Abstracts, vol. 103: 171707k (1985).
Pharmacology, vol. 103, p. 45 (1985).
Takuya Fujuita et al., “Alteration of biopharmaceutical properties of drugs by their conjugation with water-soluble macromolecules: uricase-dextran conjugate,”Journal of Controlled Release, vol. 11, pp. 149-156 (1990).
Te Piao King et al., “Immunochemical studies of dextran coupled ragweed pollen allergen, antigen E1,”Archives of Biochemistry and Biophysics, pp. 464-473 (1975).
Fu-Tong Liu et al., “Immunological tolerance to allergenic protein determinants; A therapeutic approach for selective inhibition of IgE antibody production,”Proc. Natl., Acad. Sci. USA, vol. 76, No. 3, pp. 1430-1434 (1979).
Hiroshi Maeda et al., “Conjugation of Poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties,”J. Med. Chem., vol. 28, pp. 455-461 (1985).
M. Okada et al., “Suppression of IgE antibody response against ovalburnin by the chemical conjugate of ovalburnin with a polyaspartic acid derivative,”Int. Archs Allergy appl. Immun., vol. 76, pp. 79-81 (1985).
Mitsuko USUI et al., “IgE-selective and antigen-specific unresponsiveness in mice,”The Journal of Immunology, vol. 122, No. 4, pp. 1266-72 (1979).
Berry et al., (1998) J. Biochem. 124: 434-439.
M.M. Maimone et al., “Structure of A Dermatan Sulfate Hexasaccharide That Binds To Heparin Cofactor II With High Affinity,” J. of Bio. Chem., vol. 265, No. 30, pp. 18263-18271 (1990).
Uno Takeji et al., “Evaluation for Antithrombogenicity on the Surface of Heparinized Biomedical Material Using Thrombin-Antithrombin III Complex,” Chemical Abstracts, vol. 122, No. 25, Abstract No. 306176 (Jun. 19, 1995).
M.W.C. Hatton et al., “Inhibition of Thrombin By Antithrombin III in the Presence of Certain Glycosaminoglycans Found in the Mammalian Aorta,” Thrombosis Research, 13:4, 655-670 (Apr. 24, 1978).
M. Verstraete, “Prevention of Thrombosis in Arteries: Novel Approaches,” J. Cardiovasc. Pharmacol., 7 (Suppl. 3) S191-S205 (1985).
I Bjork et al., Permanent Activation of Antithrombin By Covalent Attachment of Heparin Oligosaccharides FEBS Letters, vol. 143, pp. 96-100 (1982).
R. Ceustermans et al., “Preparation, Characterization, and Turnover Properties of Heparin-Antithrombin III Complexes Stabilized by Covalent Bonds,” The Journal of Biological Chemistry, vol. 257, 3401-3408 (1982).
M.W.C. Hatton et al., “Tritiation of Commercial Heparins by Reaction with NaB3H4: Chemical Analysis and Biological Properties of the Product,” Analytical Biochemistry, vol. 106, 417-416 (1980).
M. Hoylaerts et al., “Covalent Complexes Between Low molecular Weight Heparin Fragments and Antithrombin III-Inhibition Kinetics and Turnover Parameters,” Thromb Haemostas, vol. 49, pp. 109-115 (1983).
M. Hoylaerts et al., “Involvement of Heparin Chain Length in the Heparin-Catalyzed Inhibition of Thrombin By Antithrombin III,” The Journal of Biological Chemistry, vol. 259, pp. 5670-5677 (1984).
C. Mattsson et al., Antithrombic Properties in Rabbits of Heparin and Heparin Fragments Covalently Coupled to Human Antithrombin III, J. Clin. Invest., vol. 75, pp. 1169-1173 (1985).
A.K.C. Chan et al., “Antithrombin-Heparin Covalent Complex A Novel Approach For Improving Thr

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods of coating a device using anti-thrombin heparin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of coating a device using anti-thrombin heparin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of coating a device using anti-thrombin heparin will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3631462

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.